301 related articles for article (PubMed ID: 33042651)
21. A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors.
Chaurasia PP; Dholariya S; Kotadiya F; Bhavsar M
Cureus; 2021 Sep; 13(9):e18300. PubMed ID: 34722075
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus.
Yandrapalli S; Aronow WS
J Thorac Dis; 2017 Jul; 9(7):2124-2134. PubMed ID: 28840014
[TBL] [Abstract][Full Text] [Related]
24. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
[TBL] [Abstract][Full Text] [Related]
25. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
26. The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review.
Giri Ravindran S; Kakarla M; Ausaja Gambo M; Yousri Salama M; Haidar Ismail N; Tavalla P; Uppal P; Mohammed SA; Rajashekar S; Hamid P
Cureus; 2022 May; 14(5):e25476. PubMed ID: 35800782
[TBL] [Abstract][Full Text] [Related]
27. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
28. Adverse effects and safety of SGLT-2 inhibitors.
Halimi S; Vergès B
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
[TBL] [Abstract][Full Text] [Related]
29. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
Grenet G; Ribault S; Nguyen GB; Glais F; Metge A; Linet T; Kassai-Koupai B; Cornu C; Bejan-Angoulvant T; Erpeldinger S; Boussageon R; Gouraud A; Bonnet F; Cucherat M; Moulin P; Gueyffier F
PLoS One; 2019; 14(6):e0217701. PubMed ID: 31237921
[TBL] [Abstract][Full Text] [Related]
30. Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review.
Sarker A; Ramesh AS; Munoz C; Jamil D; Tran HH; Mansoor M; Butt SR; Satnarine T; Ratna P; Hamid P
Cureus; 2022 Sep; 14(9):e29069. PubMed ID: 36249645
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
[TBL] [Abstract][Full Text] [Related]
32. Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms.
Li W; Yu K; Sun S
Pharmazie; 2020 Jun; 75(6):224-229. PubMed ID: 32539914
[TBL] [Abstract][Full Text] [Related]
33. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
34. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
35. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
[TBL] [Abstract][Full Text] [Related]
36. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
Kramer CK; Zinman B
Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
[TBL] [Abstract][Full Text] [Related]
37. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure.
Sharma A; Ezekowitz JA
Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988
[TBL] [Abstract][Full Text] [Related]
38. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
39. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
Saisho Y
Diseases; 2020 May; 8(2):. PubMed ID: 32403420
[TBL] [Abstract][Full Text] [Related]
40. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
Milonas D; Tziomalos K
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
